International Society on Thrombosis and Haemostasis, Inc.
Special Industry Symposia
Enter Registration Site

Sunday, June 21, 2015

Room: 718

Download Program Flyer
Broadening horizons in the treatment of haemophilia and rare bleeding disorders: rFVIII (turoctocog alfa), rFXIII (catridecacog) and N9-GP

Novo Nordisk

Moderators: David Lillicrap (Canada) and Stephanie Seremetis (United States)

Lecture Time Lecture Title Speaker
15:30 - 15:40 Welcome  
15:40–16:05 Designing turoctocog alfa: how the process defines the product Marianne Kjalke (Denmark)
16:05 - 16:30 A fresh look at guardian™ 2: latest interim analysis from the turoctocog alfa extension study Johannes Oldenburg (Germany)
16:30 - 16:55 rFXIII: charting a new course in the treatment of a very rare deficiency Diane Nugent (United States)
16:55 - 17:20 N9-GP: translating the pharmacokinetic profile to clinical efficacy – results from the phase 3 trial in paediatric haemophilia B patients Manuel Carcao (Canada)
17:20 - 17:30 Close  

All Corporate Symposia ISTH 2015 Daily Schedule
 Key Dates

March 11, 2015
Early Registration Deadline

June 15, 2015
Online Registration Deadline

June 20-25, 2015
ISTH 2015